Core Insights - Tiziana Life Sciences announced significant immunologic findings from the treatment of a moderate Alzheimer's Disease patient with intranasal foralumab, indicating its potential as a breakthrough therapy [1][5] Immunologic Findings - Transcriptional analysis of white blood cells before and after foralumab therapy showed profound immune modulatory effects, with significant changes in CD4 cells, CD8 cells, and monocytes, linking immune effects to reduced brain inflammation [2] - An unexpected increase in phagocytosis markers in classical monocytes suggests that nasal foralumab may enhance the clearance of amyloid plaques, potentially opening new treatment avenues for Alzheimer's Disease [3] Expert Commentary - Dr. Howard Weiner highlighted the promising reduction in microglial inflammation and unique immune changes observed in the treated Alzheimer's patient, indicating a step forward in understanding foralumab's therapeutic role in neuroinflammatory diseases [4] - Ivor Elrifi, CEO of Tiziana, emphasized the dual benefits of nasal foralumab in reducing brain inflammation and influencing amyloid pathology, with the treatment being well tolerated and continued by the patient [4] Company Commitment - The findings represent a significant milestone in developing novel therapies for Alzheimer's Disease, underscoring Tiziana Life Sciences' commitment to advancing transformative treatments for neurodegenerative disorders [5] About Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when dosed intranasally, with ongoing studies showing improvements or stability in patients with Non-Active Secondary Progressive Multiple Sclerosis [6][7] - It is the only fully human anti-CD3 monoclonal antibody currently in clinical development, representing a novel approach for treating neuroinflammatory and neurodegenerative diseases [7] Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies, with intranasal foralumab demonstrating a favorable safety profile and clinical response in studies [8][9]